结核病药物市场规模、份额和趋势分析报告：按疾病类型（活动性结核病、潜伏性结核病）、治疗方法、给药途径、製剂、分销渠道、地区、细分市场预测，2023 ～ 2030 年

结核病药物市场的增长和趋势

根据 Grand View Research, Inc. 的最新报告，2023 年至 2030 年全球结核病药物市场规模将达到 29.9 亿美元，复合年增长率为 5.09%。结核病药物的需求预计将受结核病流行率上升的驱动。

根据世界卫生组织的《2022 年全球结核病报告》，估计 2021 年将有 1060 万人受此影响，比 2020 年增长 4.5%，约有 160 万人死亡。 这种高死亡率表明市场上对具有成本效益和高效的药物的需求未得到满足。

从 2020 年到 2021 年，耐药结核病 (DR-TB) 的负担增加了 3%，2021 年新增 450,000 例利福平耐药结核病病例。 这是多年来第一次报告患有结核病和耐药结核病的人数有所增加。 2021 年 COVID-19 大流行扰乱了许多服务，包括结核病护理。 然而，它的影响在结核病应对中受到严重影响。 此外，目前称为 BCG 的疫苗已有 100 多年历史，对成人的疗效有限，限制了其控制感染的能力。 因此，治疗剂存在商机。

耐多药和广泛耐药结核病的发病率不断上升，进一步推动了对提供适当疗法的需求。 2022 年 12 月，世卫组织发布了更新后的综合指南，其中显着改进了耐药结核病的治疗。 该指南总结并推荐使用一种新的 6 个月口服方案 (BPaLM)，该方案由普托马尼、贝达奎林、莫西沙星和利奈唑胺组成，用于治疗 MDR/RR-TB 患者。 BPaLM 方案有望缩短治疗时间并带来更好的结果。

此外，各大公司都专注于联合研究和合作，以开发新型结核病药物并保持市场竞争力。 例如，2021 年 7 月，一个由来自 13 个国家的 30 个合作伙伴组成的新联盟正式成立，以推进结核病药物的发展。 该项目是 UNITE4TB，这是一项投资约 1.98 亿美元的七年计划，旨在加速和改进治疗方法。 此外，诸如 Ni-kshay Mitra 等于 2022 年 9 月启动的计划正在兴起，目的是到 2025 年底在印度终结并针对结核病。

结核病药物市场报告要点。

• 到 2022 年，由于患病率和復发率增加，活动性结核病将成为主流。
• 由于需求不断增加以及为开发新的二线疗法而加大的研发力度，预计二线疗法部分在预测期内将呈现最快的增长速度。
• 到 2022 年，由于有许多片剂形式的药物可供使用，口服製剂将主导市场。
• 由于治疗资金减少和疾病诊断率降低，COVID-19 大流行对市场产生了负面影响。
• 到 2022 年，MEA 将占据最大的市场份额。 这是由于加大了对疾病的早期诊断的努力和增加了治疗的采用。

内容

第 1 章结核病药物市场：研究方法和范围

• 市场细分
  • 细分范围
  • 区域范围
• 调查方法
• 信息采购
  • 购买的数据库
  • GVR 内部数据库
  • 次要信息
  • 初步调查
  • 初步调查的详细信息
• 信息或数据分析
  • 数据分析模型
• 市场製定和验证
• 模型详细信息
  • 商品流分析
    • 方法 1：商品流方法
    • 方法 2：使用自下而上的方法按国家/地区进行市场预测
    • 方法 2：使用自上而下的方法逐个国家/地区进行市场估算
• 全球市场：CAGR 计算
• 次要信息列表
• 目的
• 缩写列表

第 2 章结核病药物市场：执行摘要

• 市场概况
• 片段快照
• 竞争格局快照

第 3 章结核病药物市场：行业展望

• 市场系列展望
  • 母市场沿袭预测
  • 相关/子公司市场前景
• 描绘渗透率和增长前景
• 市场动态
  • 市场驱动力
    • 结核病患病率上升
    • 增加对医疗保健基础设施的投资
    • 不断增长的老年人口
  • 市场製约因素分析
    • 耐多药结核病的高昂费用
    • 与抗结核药物相关的副作用
• SWOT 分析，按因素（政治和法律、经济和技术）
• 行业分析 - 搬运工
• 报销和监管场景
• 主要交易和战略联盟
  • 新产品发布
  • 得到
  • 分机
  • 伙伴关係
  • 营销和推广

第 4 章结核病药物市场：竞争格局

• 近期发展和影响分析：主要市场进入者
  • 安索夫矩阵
• 公司分类
  • 创新者
    • 市场差异化因素
• 供应商情况
  • 主要分销商和渠道合作伙伴列表
  • 主要客户
  • 2022 年主要参与者的市场份额分析
• 上市公司
  • 竞争仪錶盘分析
• 私人公司
  • 主要初创企业名单
• 本地网络地图

第 5 章结核病药物市场：疾病类型的业务分析

• 定义和范围
• 2022 年和 2030 年按疾病类型划分的市场份额分析
• 2018-2030 年按疾病类型划分的全球结核病药物市场
• 结核病药物市场：疾病类型的变化分析
• 活动性肺结核
• 潜伏性肺结核

第 6 章结核病药物市场：治疗业务分析

• 定义和范围
• 2022 年和 2030 年治疗市场份额分析
• 2018-2030 年全球治疗结核病药物市场
• 结核病治疗市场：治疗波动分析
• 一线治疗
• 二级治疗

第 7 章结核病药物市场：给药途径业务分析

• 定义和范围
• 2022 年和 2030 年行政程序市场份额分析
• 全球结核病药物市场，按给药途径，2018-2030 年
• 结核病治疗市场：给药途径的变化分析
• 口语
• 家长
• 其他

第 8 章结核病药物市场：剂型业务分析

• 定义和范围
• 剂型市场份额分析，2022 年和 2030 年
• 全球结核病药物市场，按配方，2018-2030 年
• 结核病药物市场：配方变化分析
• 药丸
• 胶囊
• 注射
• 其他

第 9 章结核病药物市场：分销渠道的业务分析

• 定义和范围
• 2022 年和 2030 年分销渠道市场份额分析
• 全球结核病药物市场，按分销渠道，2018-2030 年
• 结核病药物市场：分销渠道波动分析
• 医院药房
• 零售药房
• 在线药店
• 其他

第 10 章结核病药物市场：区域业务分析

• 定义和范围
• 2022 年和 2030 年区域市场份额分析
• 区域市场仪表板
• 区域市场概况
• SWOT 分析，按因素（政治和法律、经济和技术）
  • 北美
  • 欧洲
  • 亚太地区
  • 拉丁美洲
  • 母马
• 2022-2030 年市场规模、预测、趋势分析
• 北美
  • 美国
    • 主要国家动态
    • 监管框架
    • 竞争场景
    • 导出和导入场景
    • 投资场景
  • 加拿大
    • 主要国家动态
    • 监管框架
    • 竞争场景
    • 进出口方案
    • 投资场景
• 欧洲
  • 英国
    • 主要国家动态
    • 监管框架
    • 竞争场景
    • 导出和导入场景
    • 投资场景
  • 德国
    • 主要国家动态
    • 监管框架
    • 竞争场景
    • 导出和导入场景
    • 投资场景
  • 西班牙
    • 主要国家动态
    • 监管框架
    • 竞争场景
    • 进出口方案
    • 投资场景
  • 法国
    • 主要国家动态
    • 监管框架
    • 竞争场景
    • 进出口方案
    • 投资场景
  • 意大利
    • 主要国家动态
    • 监管框架
    • 竞争场景
    • 进出口方案
    • 投资场景
  • 俄罗斯
    • 监管框架
    • 竞争场景
    • 导出和导入方案
    • 投资场景
  • 丹麦
    • 主要国家动态
    • 监管框架
    • 竞争场景
    • 导出和导入场景
    • 投资场景
  • 瑞典
    • 主要国家动态
    • 监管框架
    • 竞争场景
    • 导出和导入方案
    • 投资场景
  • 挪威
    • 主要国家动态
    • 监管框架
    • 竞争场景
    • 导出和导入方案
    • 投资场景
• 亚太地区
  • 日本
    • 主要国家动态
    • 监管框架
    • 竞争场景
    • 导出和导入方案
    • 投资场景
  • 中国
    • 主要国家动态
    • 监管框架
    • 竞争场景
    • 进出口方案
    • 投资场景
  • 印度
    • 主要国家动态
    • 监管框架
    • 竞争场景
    • 进出口方案
    • 投资场景
  • 韩国
    • 主要国家动态
    • 监管框架
    • 竞争场景
    • 导出和导入方案
    • 投资场景
  • 泰国
    • 主要国家动态
    • 监管框架
    • 竞争场景
    • 导出和导入方案
    • 投资场景
  • 澳大利亚
    • 主要国家动态
    • 监管框架
    • 竞争场景
    • 导出和导入场景
    • 投资场景
• 拉丁美洲
  • 巴西
    • 主要国家动态
    • 监管框架
    • 竞争场景
    • 导出和导入场景
    • 投资场景
  • 墨西哥
    • 主要国家动态
    • 监管框架
    • 竞争场景
    • 导出和导入场景
    • 投资场景
  • 阿根廷
    • 主要国家动态
    • 监管框架
    • 竞争场景
    • 导出和导入方案
    • 投资场景
• 多边环境协定
  • 南非
    • 主要国家动态
    • 监管框架
    • 竞争场景
    • 导出和导入方案
    • 投资场景
  • 沙特阿拉伯
    • 主要国家动态
    • 监管框架
    • 竞争场景
    • 导出和导入场景
    • 投资场景
  • 阿拉伯联合酋长国
    • 主要国家动态
    • 监管框架
    • 竞争场景
    • 导出和导入场景
    • 投资场景
  • 科威特
    • 主要国家动态
    • 监管框架
    • 竞争场景
    • 导出和导入场景
    • 投资场景

第 11 章结核病药物市场：公司概况

• 公司简介
  • 阿斯利康
    • 公司简介
    • 财务业绩
    • 产品基准
    • 战略举措
  • 强生服务公司
    • 公司简介
  • 2.财务业绩
    • 产品基准
    • 战略举措
  • 礼来公司
    • 公司简介
    • 财务业绩
    • 产品基准
    • 战略举措
  • F. Hoffmann-La Roche Ltd.
    • 公司简介
    • 财务业绩
    • 产品基准
    • 战略举措
  • Viatris Inc.（Mylan NV）
    • 公司简介
    • 财务业绩
    • 产品基准
    • 战略举措
  • 梯瓦製药工业有限公司
    • 公司简介
    • 财务业绩
    • 产品基准
    • 战略举措
  • 赛诺菲
    • 公司简介
    • 财务业绩
    • 产品基准
    • 战略举措
  • 诺华公司
    • 公司简介
    • 财务业绩
    • 产品基准
    • 战略举措
  • 太阳製药工业有限公司
    • 公司简介
    • 财务业绩
    • 产品基准
    • 战略举措
  • 辉瑞公司
    • 公司简介
    • 财务业绩
    • 产品基准
    • 战略举措

Tuberculosis Therapeutics Market Growth & Trends:

The global tuberculosis therapeutics market size is expected to reach USD 2.99 billion, expanding at a CAGR of 5.09% from 2023 to 2030, according to a new report by Grand View Research, Inc., The demand for TB therapeutics is attributable to the rising prevalence of tuberculosis. According to the World Health Organization's 2022 Global TB report, an estimated 10.6 million people suffered in 2021, a 4.5% increase from 2020, and has accounted for the death of around 1.6 million people. This high rate of mortality demonstrates an unmet need for cost-effective and efficient drugs in the market.

The burden of drug-resistant tuberculosis (DR-TB) increased by 3% between 2020 and 2021, with 450 000 new cases of rifampicin-resistant tuberculosis in 2021. This is the first time in past few years that an increase in the number of people suffering from TB and DR-TB has been reported. The COVID-19 pandemic in 2021 has disrupted many services, including TB care. However, the impact has been severely seen in the TB response. Moreover, because the current vaccine, known as BCG, is over 100 years old and has limited efficacy in adults, the ability to control transmission is limited. Thus, creating business opportunity for therapeutics.

The rising incidence of multidrug-resistant and extensively drug-resistant tuberculosis has further propelled the demand for providing appropriate therapeutics. In December 2022 , the WHO released an updated consolidated guideline featuring major improvements on the treatment of drug-resistant TB. The guideline summarizes and recommends the use of a novel all-oral 6-month regimen consisting of pretomanid, bedaquiline, moxifloxacin, and linezolid (BPaLM) for treatment of patients suffering from MDR/RR-TB. The BPaLM regimen is expected to shorten the duration and offer better outcome of treatment.

Furthermore, key players are focusing on collaborations and partnerships to develop novel tuberculosis therapeutics and to maintain their competitive position in the market. For instance, in July 2021 , to advance tuberculosis therapeutics a new consortium of 30 partners from 13 countries has officially launched. The project is UNITE4TB and is a 7-year plan with an investment of around USD 198 million with a goal to accelerate and improve therapeutics. Moreover, initiatives such as the Ni-kshay Mitra launched in September 2022, have come up in India intending to eliminate and target tuberculosis by the end of 2025.

Tuberculosis Therapeutics Market Report Highlights:

• Active TB segment dominated et in 2022 and is attributable to the increasing prevalence and recurrence of condition

• Second line therapy segment is expected to show fastest growth rate over the forecast period owing to increasing demand and the rising research and development for development of newer second-line therapy drugs

• Oral segment dominated the market in 2022 attributable to the availability of a large number of drugs in form of tablets.

• The COVID-19 pandemic influenced the market adversely attributable to the reduced funding for therapeutics and decline in diagnosis rate of disease.

• MEA held the largest market share in 2022 which can be attributed to the enhanced focus on early diagnosis of the disease and improvement in adoption rate of treatments.

Table of Contents

Chapter 1 Tuberculosis Therapeutics Market: Methodology And Scope

• 1.1 Market Segmentation
  • 1.1.1 Segment Scope
  • 1.1.2 Regional Scope
  • 1.1.3 Estimates And Forecast Timeline
• 1.2 Research Methodology
• 1.3 Information Procurement
  • 1.3.1 Purchased Database
  • 1.3.2 Gvr's Internal Database
  • 1.3.3 Secondary Sources
  • 1.3.4 Primary Research
  • 1.3.5 Details Of Primary Research
• 1.4 Information Or Data Analysis
  • 1.4.1 Data Analysis Models
• 1.5 Market Formulation & Validation
• 1.6 Model Details
  • 1.6.1 Commodity Flow Analysis
    • 1.6.1.1 Approach 1: Commodity Flow Approach
    • 1.6.1.2 Approach 2: Country Wise Market Estimation Using Bottom Up Approach
    • 1.6.1.3 Approach 2: Country Wise Market Estimation Using Top Down Approach
• 1.7 Global Market: Cagr Calculation
• 1.8 List Of Secondary Sources
• 1.9 Objectives
  • 1.9.1 Objective 1
  • 1.9.2 Objective 2
• 1.11 List of Abbreviations

Chapter 2 Tuberculosis Therapeutics Market: Executive Summary

• 2.1 Market Snapshot
• 2.2 Segment Snapshot
• 2.3 Competitive Landscape Snapshot

Chapter 3 Tuberculosis Therapeutics Market: Industry Outlook

• 3.1 Market Lineage Outlook
  • 3.1.1 Parent Market Lineage Outlook
  • 3.1.2 Related/Ancillary Market Outlook
• 3.2 Penetration & Growth Prospect Mapping
• 3.3 Market Dynamics
  • 3.3.1 Market Drivers
    • 3.3.1.1 Rise in the prevalence of tuberculosis
    • 3.3.1.2 Increasing investment for healthcare infrastructure
    • 3.3.1.3 Growing number of geriatric population
  • 3.3.2 Market Restraint Analysis
    • 3.3.2.1 High cost of multidrug-resistant TB
    • 3.3.2.2 Side effects linked with anti-tuberculosis drugs
• 3.4 SWOT Analysis, By Factor (Political & Legal, Economic and Technological)
• 3.5 Industry Analysis - Porter's
• 3.6 Reimbursement & Regulatory Scenario
• 3.7 Major Deals & Strategic Alliances
  • 3.7.1 New Product Launch
  • 3.7.2 Acquisition
  • 3.7.3 Expansion
  • 3.7.4 Partnerships
  • 3.7.5 Marketing & Promotions

Chapter 4 Tuberculosis Therapeutics Market: Competitive Landscape

• 4.1 Recent Developments & Impact Analysis, By Key Market Participants
  • 4.1.1 Ansoff Matrix
• 4.2 Company Categorization
  • 4.2.1 Innovators
    • 4.2.1.1 Market Differentiators
• 4.3 Vendor Landscape
  • 4.3.1 List Of Key Distributors And Channel Partners
  • 4.3.2 Key Customers
  • 4.3.3 Key Company Market Share Analysis, 2022
• 4.4 Public Companies
  • 4.4.1 Competitive Dashboard Analysis
• 4.5 Private Companies
  • 4.5.1 List Of Key Emerging Companies
• 4.6 Regional Network Map

Chapter 5 Tuberculosis Therapeutics Market: Disease Type Business Analysis

• 5.1 Definition And Scope
• 5.2 Disease Type Market Share Analysis, 2022 & 2030
• 5.3 Global Tuberculosis Therapeutics Market, By Disease Type, 2018 To 2030
• 5.4 Tuberculosis Therapeutics Market: Disease Type Movement Analysis
• 5.5 Active Tb
  • 5.5.1 Active Tb Market Estimates And Forecast, 2018 - 2030 (USD Million)
• 5.6 Latent Tb
  • 5.6.1 Latent Tb Market Estimates And Forecast, 2018 - 2030 (USD Million)

Chapter 6 Tuberculosis Therapeutics Market: Therapy Business Analysis

• 6.1 Definition and Scope
• 6.2 Therapy Market Share Analysis, 2022 & 2030
• 6.3 Global Tuberculosis Therapeutics Market, By Therapy, 2018 To 2030
• 6.4 Tuberculosis Therapeutics Market: Therapy Movement Analysis
• 6.5 First-Line Therapy
  • 6.5.1 First-Line Therapy Market Estimates And Forecast, 2018 - 2030 (USD Million)
• 6.6 Second-Line Therapy
  • 6.6.1 Second-Line Therapy Market Estimates And Forecast, 2018 - 2030 (USD Million)

Chapter 7 Tuberculosis Therapeutics Market: Route of Administration Business Analysis

• 7.1 Definition and Scope
• 7.2 Route of Administration Market Share Analysis, 2022 & 2030
• 7.3 Global Tuberculosis Therapeutics Market, By Route of Administration, 2018 To 2030
• 7.4 Tuberculosis Therapeutics Market: Route of Administration Movement Analysis
• 7.5 Oral
  • 7.5.1 Oral Market Estimates And Forecast, 2018 - 2030 (USD Million)
• 7.6 Parentral
  • 7.6.1 Parentral Market Estimates And Forecast, 2018 - 2030 (USD Million)
• 7.7 Others
  • 7.7.1 Others Market Estimates And Forecast, 2018 - 2030 (USD Million)

Chapter 8 Tuberculosis Therapeutics Market: Dosage Form Business Analysis

• 8.1 Definition and Scope
• 8.2 Dosage Form Market Share Analysis, 2022 & 2030
• 8.3 Global Tuberculosis Therapeutics Market, By Dosage Form, 2018 To 2030
• 8.4 Tuberculosis Therapeutics Market: Dosage Form Movement Analysis
• 8.5 Tablets
  • 8.5.1 Tablets Market Estimates And Forecast, 2018 - 2030 (USD Million)
• 8.6 Capsules
  • 8.6.1 Capsules Market Estimates And Forecast, 2018 - 2030 (USD Million)
• 8.7 Injections
  • 8.7.1 Injections Market Estimates And Forecast, 2018 - 2030 (USD Million)
• 8.8 Others
  • 8.8.1 Others Market Estimates And Forecast, 2018 - 2030 (USD Million)

Chapter 9 Tuberculosis Therapeutics Market: Distribution Channel Business Analysis

• 9.1 Definition and Scope
• 9.2 Distribution Channel Market Share Analysis, 2022 & 2030
• 9.3 Global Tuberculosis Therapeutics Market, By Distribution Channel, 2018 To 2030
• 9.4 Tuberculosis Therapeutics Market: Distribution Channel Movement Analysis
• 9.5 Hospital Pharmacy
  • 9.5.1 Hospital Pharmacy Market Estimates And Forecast, 2018 - 2030 (USD Million)
• 9.6 Retail Pharmacy
  • 9.6.1 Reatail Pharmacy Market Estimates And Forecast, 2018 - 2030 (USD Million)
• 9.7 Online Pharmacy
  • 9.7.1 Online Pharmacy Market Estimates And Forecast, 2018 - 2030 (USD Million)
• 9.8 Others
  • 9.8.1 Others Market Estimates And Forecast, 2018 - 2030 (USD Million)

Chapter 10 Tuberculosis Therapeutics Market: Regional Business Analysis

• 10.1 Definition & Scope
• 10.2 Regional Market Share Analysis, 2022 & 2030
• 10.3 Regional Market Dashboard
• 10.4 Regional Market Snapshot
• 10.5 SWOT Analysis, By Factor (Political & Legal, Economic And Technological)
  • 10.5.1 North America
  • 10.5.2 Europe
  • 10.5.3 Asia Pacific
  • 10.5.4 Latin America
  • 10.5.5 Mea
• 10.6 Market Size, & Forecasts, Trend Analysis, 2022 to 2030
• 10.7 North America
  • 10.7.1 North America Tuberculosis Therapeutics Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • 10.7.2 U.S.
    • 10.7.2.1 U.S. Tuberculosis Therapeutics Market, 2018 - 2030 (USD Million)
    • 10.7.2.2 Key Country Dynamics
    • 10.7.2.3 Regulatory Framework
    • 10.7.2.4 Competitive Scenario
    • 10.7.2.5 Import Export Scenario
    • 10.7.2.6 Investments Scenario
  • 10.7.3 Canada
    • 10.7.3.1 Canada tuberculosis therapeutics market, 2018 - 2030 (USD Million)
    • 10.7.3.2 Key Country Dynamics
    • 10.7.3.3 Regulatory Framework
    • 10.7.3.4 Competitive Scenario
    • 10.7.3.5 Import Export Scenario
    • 10.7.3.6 Investments Scenario
• 10.8 Europe
  • 10.8.1 Europe Tuberculosis Therapeutics Market, 2018 - 2030 (USD Million)
  • 10.8.2 U.K.
    • 10.8.2.1 U.K. Tuberculosis Therapeutics Market, 2018 - 2030 (USD Million)
    • 10.8.2.2 Key Country Dynamics
    • 10.8.2.3 Regulatory Framework
    • 10.8.2.4 Competitive Scenario
    • 10.8.2.5 Import Export Scenario
    • 10.8.2.6 Investments Scenario
  • 10.8.3 Germany
    • 10.8.3.1 Germany Tuberculosis Therapeutics Market, 2018 - 2030 (USD Million)
    • 10.8.3.2 Key Country Dynamics
    • 10.8.3.3 Regulatory Framework
    • 10.8.3.4 Competitive Scenario
    • 10.8.3.5 Import Export Scenario
    • 10.8.3.6 Investments Scenario
  • 10.8.4 Spain
    • 10.8.4.1 Spain tuberculosis therapeutics market, 2018 - 2030 (USD Million)
    • 10.8.4.2 Key Country Dynamics
    • 10.8.4.3 Regulatory Framework
    • 10.8.4.4 Competitive Scenario
    • 10.8.4.5 Import Export Scenario
    • 10.8.4.6 Investments Scenario
  • 10.8.5 France
    • 10.8.5.1 France tuberculosis therapeutics market, 2018 - 2030 (USD Million)
    • 10.8.5.2 Key Country Dynamics
    • 10.8.5.3 Regulatory Framework
    • 10.8.5.4 Competitive Scenario
    • 10.8.5.5 Import Export Scenario
    • 10.8.5.6 Investments Scenario
  • 10.8.6 Italy
    • 10.8.6.1 Italy tuberculosis therapeutics market, 2018 - 2030 (USD Million)
    • 10.8.6.2 Key Country Dynamics
    • 10.8.6.3 Regulatory Framework
    • 10.8.6.4 Competitive Scenario
    • 10.8.6.5 Import Export Scenario
    • 10.8.6.6 Investments Scenario
  • 10.8.7 Russia
    • 10.8.7.1 Russia tuberculosis therapeutics market, 2018 - 2030 (USD Million)
    • 10.8.7.3 Regulatory Framework
    • 10.8.7.4 Competitive Scenario
    • 10.8.7.5 Import Export Scenario
    • 10.8.7.6 Investments Scenario
  • 10.8.8 Denmark
    • 10.8.8.1 Denmark Tuberculosis Therapeutics Market, 2018 - 2030 (USD Million)
    • 10.8.8.2 Key Country Dynamics
    • 10.8.8.3 Regulatory Framework
    • 10.8.8.4 Competitive Scenario
    • 10.8.8.5 Import Export Scenario
    • 10.8.8.6 Investments Scenario
  • 10.8.9 Sweden
    • 10.8.9.1 Sweden Tuberculosis Therapeutics Market, 2018 - 2030 (USD Million)
    • 10.8.9.2 Key Country Dynamics
    • 10.8.9.3 Regulatory Framework
    • 10.8.9.4 Competitive Scenario
    • 10.8.9.5 Import Export Scenario
    • 10.8.9.6 Investments Scenario
  • 10.8.10 Norway
    • 10.8.10.1 Norway Tuberculosis Therapeutics Market, 2018 - 2030 (USD Million)
    • 10.8.10.2 Key Country Dynamics
    • 10.8.10.3 Regulatory Framework
    • 10.8.10.4 Competitive Scenario
    • 10.8.10.5 Import Export Scenario
    • 10.8.10.6 Investments Scenario
• 10.9 Asia Pacific
  • 10.9.1 Asia-Pacific Tuberculosis Therapeutics Market, 2018 - 2030 (USD Million)
  • 10.9.2 Japan
    • 10.9.2.1 Japan Tuberculosis Therapeutics Market, 2018 - 2030 (USD Million)
    • 10.9.2.2 Key Country Dynamics
    • 10.9.2.3 Regulatory Framework
    • 10.9.2.4 Competitive Scenario
    • 10.9.2.5 Import Export Scenario
    • 10.9.2.6 Investments Scenario
  • 10.9.3 China
    • 10.9.3.1 China Tuberculosis Therapeutics Market, 2018 - 2030 (USD Million)
    • 10.9.3.2 Key Country Dynamics
    • 10.9.3.3 Regulatory Framework
    • 10.9.3.4 Competitive Scenario
    • 10.9.3.5 Import Export Scenario
    • 10.9.3.6 Investments Scenario
  • 10.9.4 India
    • 10.9.4.1 India Tuberculosis Therapeutics Market, 2018 - 2030 (USD Million)
    • 10.9.4.2 Key Country Dynamics
    • 10.9.4.3 Regulatory Framework
    • 10.9.4.4 Competitive Scenario
    • 10.9.4.5 Import Export Scenario
    • 10.9.4.6 Investments Scenario
  • 10.9.5 South Korea
    • 10.9.5.1 South Korea Tuberculosis Therapeutics Market, 2018 - 2030 (USD Million)
    • 10.9.5.2 Key Country Dynamics
    • 10.9.5.3 Regulatory Framework
    • 10.9.5.4 Competitive Scenario
    • 10.9.5.5 Import Export Scenario
    • 10.9.5.6 Investments Scenario
  • 10.9.6 Thailand
    • 10.9.6.1 Thailand Tuberculosis Therapeutics Market, 2018 - 2030 (USD Million)
    • 10.9.6.2 Key Country Dynamics
    • 10.9.6.3 Regulatory Framework
    • 10.9.6.4 Competitive Scenario
    • 10.9.6.5 Import Export Scenario
    • 10.9.6.6 Investments Scenario
  • 10.9.7 Australia
    • 10.9.7.1 Australia tuberculosis therapeutics market, 2018 - 2030 (USD Million)
    • 10.9.7.2 Key Country Dynamics
    • 10.9.7.3 Regulatory Framework
    • 10.9.7.4 Competitive Scenario
    • 10.9.7.5 Import Export Scenario
    • 10.9.7.6 Investments Scenario
• 10.10 Latin America
  • 10.10.1 Latin America Tuberculosis Therapeutics Market, 2018 - 2030 (USD Million)
  • 10.10.2 Brazil
    • 10.10.2.1 Brazil Tuberculosis Therapeutics Market, 2018 - 2030 (USD Million)
    • 10.10.2.2 Key Country Dynamics
    • 10.10.2.3 Regulatory Framework
    • 10.10.2.4 Competitive Scenario
    • 10.10.2.5 Import Export Scenario
    • 10.10.2.6 Investments Scenario
  • 10.10.3 Mexico
    • 10.10.3.1 Mexico Tuberculosis Therapeutics Market, 2018 - 2030 (USD Million)
    • 10.10.3.2 Key Country Dynamics
    • 10.10.3.3 Regulatory Framework
    • 10.10.3.4 Competitive Scenario
    • 10.10.3.5 Import Export Scenario
    • 10.10.3.6 Investments Scenario
  • 10.10.4 Argentina
    • 10.10.4.1 Argentina Tuberculosis Therapeutics Market, 2018 - 2030 (USD Million)
    • 10.10.4.2 Key Country Dynamics
    • 10.10.4.3 Regulatory Framework
    • 10.10.4.4 Competitive Scenario
    • 10.10.4.5 Import Export Scenario
    • 10.10.4.6 Investments Scenario
• 10.11 MEA
  • 10.11.1 MEA Tuberculosis Therapeutics Market, 2018 - 2030 (USD Million)
  • 10.11.2 South Africa
    • 10.11.2.1 South Africa Tuberculosis Therapeutics Market, 2018 - 2030 (USD Million)
    • 10.11.2.2 Key Country Dynamics
    • 10.11.2.3 Regulatory Framework
    • 10.11.2.4 Competitive Scenario
    • 10.11.2.5 Import Export Scenario
    • 10.11.2.6 Investments Scenario
  • 10.11.3 Saudi Arabia
    • 10.11.3.1 Saudi Arabia Tuberculosis Therapeutics Market, 2018 - 2030 (USD Million)
    • 10.11.3.2 Key Country Dynamics
    • 10.11.3.3 Regulatory Framework
    • 10.11.3.4 Competitive Scenario
    • 10.11.3.5 Import Export Scenario
    • 10.11.3.6 Investments Scenario
  • 10.11.4 UAE
    • 10.11.4.1 UAE Tuberculosis Therapeutics Market, 2018 - 2030 (USD Million)
    • 10.11.4.2 Key Country Dynamics
    • 10.11.4.3 Regulatory Framework
    • 10.11.4.4 Competitive Scenario
    • 10.11.4.5 Import Export Scenario
    • 10.11.4.6 Investments Scenario
  • 10.11.5 Kuwait
    • 10.11.5.1 Kuwait Tuberculosis Therapeutics Market, 2018 - 2030 (USD Million)
    • 10.11.5.2 Key Country Dynamics
    • 10.11.5.3 Regulatory Framework
    • 10.11.5.4 Competitive Scenario
    • 10.11.5.5 Import Export Scenario
    • 10.11.5.6 Investments Scenario

Chapter 11 Tuberculosis Therapeutics Market: Company Profiling

• 11.1 Company Profiles
  • 11.1.1 Astrazeneca
    • 11.1.1.1 Company Overview
    • 11.1.1.2 Financial Performance
    • 11.1.1.3 Product Benchmarking
    • 11.1.1.4 Strategic Initiatives
  • 11.1.2 Johnson & Johnson Services, Inc.
    • 11.1.2.1 Company Overview
  • 11.1.2 2.Financial Performance
    • 11.1.2.3 Product Benchmarking
    • 11.1.2.4 Strategic Initiatives
  • 11.1.3 Eli Lilly And Company
    • 11.1.3.1 Company Overview
    • 11.1.3.2 Financial Performance
    • 11.1.3.3 Product Benchmarking
    • 11.1.3.4 Strategic Initiatives
  • 11.1.4 F. Hoffmann-La Roche Ltd.
    • 11.1.4.1 Company Overview
    • 11.1.4.2 Financial Performance
    • 11.1.4.3 Product Benchmarking
    • 11.1.4.4 Strategic Initiatives
  • 11.1.5 Viatris Inc. (Mylan N.V.)
    • 11.1.5.1 Company Overview
    • 11.1.5.2 Financial Performance
    • 11.1.5.3 Product Benchmarking
    • 11.1.5.4 Strategic Initiatives
  • 11.1.6 Teva Pharmaceutical Industries, Ltd.
    • 11.1.6.1 Company Overview
    • 11.1.6.2 Financial Performance
    • 11.1.6.3 Product Benchmarking
    • 11.1.6.4 Strategic Initiatives
  • 11.1.7 Sanofi
    • 11.1.7.1 Company Overview
    • 11.1.7.2 Financial Performance
    • 11.1.7.3 Product Benchmarking
    • 11.1.7.4 Strategic Initiatives
  • 11.1.8 Novartis Ag
    • 11.1.8.1 Company Overview
    • 11.1.8.2 Financial Performance
    • 11.1.8.3 Product Benchmarking
    • 11.1.8.4 Strategic Initiatives
  • 11.1.9 Sun Pharmaceutical Industries Ltd.
    • 11.1.9.1 Company Overview
    • 11.1.9.2 Financial Performance
    • 11.1.9.3 Product Benchmarking
    • 11.1.9.4 Strategic Initiatives
  • 11.1.10 Pfizer Inc.
    • 11.1.10.1 Company Overview
    • 11.1.10.2 Financial Performance
    • 11.1.10.3 Product Benchmarking
    • 11.1.10.4 Strategic Initiatives

List of Tables

• Table 1 List of Secondary Sources
• Table 2 List of Abbreviation
• Table 3 Incidence of Diseases
• Table 4 Global Tuberculosis Therapeutics Market, By Region, 2018 - 2030 (USD Million)
• Table 5 Global Tuberculosis Therapeutics Market, By Drug type, 2018 - 2030 (USD Million)
• Table 6 North America Tuberculosis Therapeutics Market, By Country, 2018 - 2030 (USD Million)
• Table 7 North America Tuberculosis Therapeutics Market, By Disease Type, 2018 - 2030 (USD Million)
• Table 8 North America Tuberculosis Therapeutics Market, By Therapy, 2018 - 2030 (USD Million)
• Table 9 North America Tuberculosis Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 10 North America Tuberculosis Therapeutics Market, By Dosage Form, 2018 - 2030 (USD Million)
• Table 11 North America Tuberculosis Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 12 U.S. Tuberculosis Therapeutics Market, By Disease Type, 2018 - 2030 (USD Million)
• Table 13 U.S. Tuberculosis Therapeutics Market, By Therapy, 2018 - 2030 (USD Million)
• Table 14 U.S. Tuberculosis Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 15 U.S. Tuberculosis Therapeutics Market, By Dosage Form, 2018 - 2030 (USD Million)
• Table 16 U.S. Tuberculosis Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 17 Canada Tuberculosis Therapeutics Market, By Disease Type, 2018 - 2030 (USD Million)
• Table 18 Canada Tuberculosis Therapeutics Market, By Therapy, 2018 - 2030 (USD Million)
• Table 19 Canada Tuberculosis Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 20 Canada Tuberculosis Therapeutics Market, By Dosage Form, 2018 - 2030 (USD Million)
• Table 21 Canada Tuberculosis Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 22 Europe Tuberculosis Therapeutics Market, By Country, 2018 - 2030 (USD Million)
• Table 23 Europe Tuberculosis Therapeutics Market, By Disease Type, 2018 - 2030 (USD Million)
• Table 24 Europe Tuberculosis Therapeutics Market, By Therapy, 2018 - 2030 (USD Million)
• Table 25 Europe Tuberculosis Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 26 Europe Tuberculosis Therapeutics Market, By Dosage Form, 2018 - 2030 (USD Million)
• Table 27 Europe Tuberculosis Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 28 Germany Tuberculosis Therapeutics Market, By Disease Type, 2018 - 2030 (USD Million)
• Table 29 Germany Tuberculosis Therapeutics Market, By Therapy, 2018 - 2030 (USD Million)
• Table 30 Germany Tuberculosis Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 31 Germany Tuberculosis Therapeutics Market, By Dosage Form, 2018 - 2030 (USD Million)
• Table 32 Germany Tuberculosis Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 33 U.K. Tuberculosis Therapeutics Market, By Disease Type, 2018 - 2030 (USD Million)
• Table 34 U.K. Tuberculosis Therapeutics Market, By Therapy, 2018 - 2030 (USD Million)
• Table 35 U.K. Tuberculosis Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 36 U.K. Tuberculosis Therapeutics Market, By Dosage Form, 2018 - 2030 (USD Million)
• Table 37 U.K. Tuberculosis Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 38 France Tuberculosis Therapeutics Market, By Disease Type, 2018 - 2030 (USD Million)
• Table 39 France Tuberculosis Therapeutics Market, By Therapy, 2018 - 2030 (USD Million)
• Table 40 France Tuberculosis Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 41 France Tuberculosis Therapeutics Market, By Dosage Form, 2018 - 2030 (USD Million)
• Table 42 France Tuberculosis Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 43 Italy Tuberculosis Therapeutics Market, By Disease Type, 2018 - 2030 (USD Million)
• Table 44 Italy Tuberculosis Therapeutics Market, By Therapy, 2018 - 2030 (USD Million)
• Table 45 Italy Tuberculosis Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 46 Italy Tuberculosis Therapeutics Market, By Dosage Form, 2018 - 2030 (USD Million)
• Table 47 Italy Tuberculosis Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 48 Spain Tuberculosis Therapeutics Market, By Disease Type, 2018 - 2030 (USD Million)
• Table 49 Spain Tuberculosis Therapeutics Market, By Therapy, 2018 - 2030 (USD Million)
• Table 50 Spain Tuberculosis Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 51 Spain Tuberculosis Therapeutics Market, By Dosage Form, 2018 - 2030 (USD Million)
• Table 52 Spain Tuberculosis Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 53 Denmark Tuberculosis Therapeutics Market, By Disease Type, 2018 - 2030 (USD Million)
• Table 54 Denmark Tuberculosis Therapeutics Market, By Therapy, 2018 - 2030 (USD Million)
• Table 55 Denmark Tuberculosis Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 56 Denmark Tuberculosis Therapeutics Market, By Dosage Form, 2018 - 2030 (USD Million)
• Table 57 Denmark Tuberculosis Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 58 Sweden Tuberculosis Therapeutics Market, By Disease Type, 2018 - 2030 (USD Million)
• Table 59 Sweden Tuberculosis Therapeutics Market, By Therapy, 2018 - 2030 (USD Million)
• Table 60 Sweden Tuberculosis Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 61 Sweden Tuberculosis Therapeutics Market, By Dosage Form, 2018 - 2030 (USD Million)
• Table 62 Sweden Tuberculosis Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 63 Norway Tuberculosis Therapeutics Market, By Disease Type, 2018 - 2030 (USD Million)
• Table 64 Norway Tuberculosis Therapeutics Market, By Therapy, 2018 - 2030 (USD Million)
• Table 65 Norway Tuberculosis Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 66 Norway Tuberculosis Therapeutics Market, By Dosage Form, 2018 - 2030 (USD Million)
• Table 67 Norway Tuberculosis Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 68 Asia Pacific Tuberculosis Therapeutics Market, By Country, 2018 - 2030 (USD Million)
• Table 69 Asia Pacific Tuberculosis Therapeutics Market, By Disease Type, 2018 - 2030 (USD Million)
• Table 70 Asia Pacific Tuberculosis Therapeutics Market, By Therapy, 2018 - 2030 (USD Million)
• Table 71 Asia Pacific Tuberculosis Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 72 Asia Pacific Tuberculosis Therapeutics Market, By Dosage Form, 2018 - 2030 (USD Million)
• Table 73 Asia Pacific Tuberculosis Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 74 Japan Tuberculosis Therapeutics Market, By Disease Type, 2018 - 2030 (USD Million)
• Table 75 Japan Tuberculosis Therapeutics Market, By Therapy, 2018 - 2030 (USD Million)
• Table 76 Japan Tuberculosis Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 77 Japan Tuberculosis Therapeutics Market, By Dosage Form, 2018 - 2030 (USD Million)
• Table 78 Japan Tuberculosis Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 79 China Tuberculosis Therapeutics Market, By Disease Type, 2018 - 2030 (USD Million)
• Table 80 China Tuberculosis Therapeutics Market, By Therapy, 2018 - 2030 (USD Million)
• Table 81 China Tuberculosis Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 82 China Tuberculosis Therapeutics Market, By Dosage Form, 2018 - 2030 (USD Million)
• Table 83 China Tuberculosis Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 84 India Tuberculosis Therapeutics Market, By Disease Type, 2018 - 2030 (USD Million)
• Table 85 India Tuberculosis Therapeutics Market, By Therapy, 2018 - 2030 (USD Million)
• Table 86 India Tuberculosis Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 87 India Tuberculosis Therapeutics Market, By Dosage Form, 2018 - 2030 (USD Million)
• Table 88 India Tuberculosis Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 89 South Korea Tuberculosis Therapeutics Market, By Disease Type, 2018 - 2030 (USD Million)
• Table 90 South Korea Tuberculosis Therapeutics Market, By Therapy, 2018 - 2030 (USD Million)
• Table 91 South Korea Tuberculosis Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 92 South Korea Tuberculosis Therapeutics Market, By Dosage Form, 2018 - 2030 (USD Million)
• Table 93 South Korea Tuberculosis Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 94 Australia Tuberculosis Therapeutics Market, By Disease Type, 2018 - 2030 (USD Million)
• Table 95 Australia Tuberculosis Therapeutics Market, By Therapy, 2018 - 2030 (USD Million)
• Table 96 Australia Tuberculosis Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 97 Australia Tuberculosis Therapeutics Market, By Dosage Form, 2018 - 2030 (USD Million)
• Table 98 Australia Tuberculosis Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 99 Thailand Tuberculosis Therapeutics Market, By Disease Type, 2018 - 2030 (USD Million)
• Table 100 Thailand Tuberculosis Therapeutics Market, By Therapy, 2018 - 2030 (USD Million)
• Table 101 Thailand Tuberculosis Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 102 Thailand Tuberculosis Therapeutics Market, By Dosage Form, 2018 - 2030 (USD Million)
• Table 103 Thailand Tuberculosis Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 104 Latin America Tuberculosis Therapeutics Market, By Country, 2018 - 2030 (USD Million)
• Table 105 Latin America Tuberculosis Therapeutics Market, By Disease Type, 2018 - 2030 (USD Million)
• Table 106 Latin America Tuberculosis Therapeutics Market, By Therapy, 2018 - 2030 (USD Million)
• Table 107 Latin America Tuberculosis Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 108 Latin America Tuberculosis Therapeutics Market, By Dosage Form, 2018 - 2030 (USD Million)
• Table 109 Latin America Tuberculosis Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 110 Brazil Tuberculosis Therapeutics Market, By Disease Type, 2018 - 2030 (USD Million)
• Table 111 Brazil Tuberculosis Therapeutics Market, By Therapy, 2018 - 2030 (USD Million)
• Table 112 Brazil Tuberculosis Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 113 Brazil Tuberculosis Therapeutics Market, By Dosage Form, 2018 - 2030 (USD Million)
• Table 114 Brazil Tuberculosis Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 115 Mexico Tuberculosis Therapeutics Market, By Disease Type, 2018 - 2030 (USD Million)
• Table 116 Mexico Tuberculosis Therapeutics Market, By Therapy, 2018 - 2030 (USD Million)
• Table 117 Mexico Tuberculosis Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 118 Mexico Tuberculosis Therapeutics Market, By Dosage Form, 2018 - 2030 (USD Million)
• Table 119 Mexico Tuberculosis Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 120 Argentina Tuberculosis Therapeutics Market, By Disease Type, 2018 - 2030 (USD Million)
• Table 121 Argentina Tuberculosis Therapeutics Market, By Therapy, 2018 - 2030 (USD Million)
• Table 122 Argentina Tuberculosis Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 123 Argentina Tuberculosis Therapeutics Market, By Dosage Form, 2018 - 2030 (USD Million)
• Table 124 Argentina Tuberculosis Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 125 Middle East & Africa Tuberculosis Therapeutics Market, By Country, 2018 - 2030 (USD Million)
• Table 126 Middle East & Africa Tuberculosis Therapeutics Market, By Disease Type, 2018 - 2030 (USD Million)
• Table 127 Middle East & Africa Tuberculosis Therapeutics Market, By Therapy, 2018 - 2030 (USD Million)
• Table 128 Middle East & Africa Tuberculosis Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 129 Middle East & Africa Tuberculosis Therapeutics Market, By Dosage Form, 2018 - 2030 (USD Million)
• Table 130 Middle East & Africa Tuberculosis Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 131 Saudi Arabia Tuberculosis Therapeutics Market, By Disease Type, 2018 - 2030 (USD Million)
• Table 132 Saudi Arabia Tuberculosis Therapeutics Market, By Therapy, 2018 - 2030 (USD Million)
• Table 133 Saudi Arabia Tuberculosis Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 134 Saudi Arabia Tuberculosis Therapeutics Market, By Dosage Form, 2018 - 2030 (USD Million)
• Table 135 Saudi Arabia Tuberculosis Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 136 South Africa Tuberculosis Therapeutics Market, By Disease Type, 2018 - 2030 (USD Million)
• Table 137 South Africa Tuberculosis Therapeutics Market, By Therapy, 2018 - 2030 (USD Million)
• Table 138 South Africa Tuberculosis Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 139 South Africa Tuberculosis Therapeutics Market, By Dosage Form, 2018 - 2030 (USD Million)
• Table 140 South Africa Tuberculosis Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 141 UAE Tuberculosis Therapeutics Market, By Disease Type, 2018 - 2030 (USD Million)
• Table 142 UAE Tuberculosis Therapeutics Market, By Therapy, 2018 - 2030 (USD Million)
• Table 143 UAE Tuberculosis Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 144 UAE Tuberculosis Therapeutics Market, By Dosage Form, 2018 - 2030 (USD Million)
• Table 145 UAE Tuberculosis Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
• Table 146 Kuwait Tuberculosis Therapeutics Market, By Disease Type, 2018 - 2030 (USD Million)
• Table 147 Kuwait Tuberculosis Therapeutics Market, By Therapy, 2018 - 2030 (USD Million)
• Table 148 Kuwait Tuberculosis Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
• Table 149 Kuwait Tuberculosis Therapeutics Market, By Dosage Form, 2018 - 2030 (USD Million)
• Table 150 Kuwait Tuberculosis Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)

List of Figures

• Fig. 1 Market Research Process
• Fig. 2 Information Procurement
• Fig. 3 Primary Research Pattern
• Fig. 4 Market Research Approaches
• Fig. 5 Value Chain-Based Sizing & Forecasting
• Fig. 6 Market Formulation & Validation
• Fig. 7 Tuberculosis Therapeutics Market Segmentation
• Fig. 8 Market Driver Relevance Analysis (Current & Future Impact)
• Fig. 9 Market Restraint Relevance Analysis (Current & Future Impact)
• Fig. 10 Market Challenge Relevance Analysis (Current & Future Impact)
• Fig. 11 Penetration & Growth Prospect Mapping
• Fig. 12 SWOT Analysis, By Factor (Political & Legal, Economic and Technological)
• Fig. 13 Porter's Five Forces Analysis
• Fig. 14 Market Penetration & Growth Prospect Mapping
• Fig. 15 Tuberculosis therapeutics market: Disease type outlook and key takeaways
• Fig. 16 Tuberculosis therapeutics market: Disease type movement analysis & market share 2022 & 2030
• Fig. 17 Active TB market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 18 Latent TB market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 19 Tuberculosis therapeutics market: Therapy outlook and key takeaways
• Fig. 20 Tuberculosis therapeutics market: Therapy movement analysis & market share 2022 & 2030
• Fig. 21 First-line therapy market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 22 Second-line therapy market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 23 Tuberculosis therapeutics market: Route of administration outlook and key takeaways
• Fig. 24 Tuberculosis therapeutics market: Route of administration movement analysis & market share 2022 & 2030
• Fig. 25 Oral market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 26 Parenteral market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 27 Others market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 28 Tuberculosis therapeutics market: Dosage form outlook and key takeaways
• Fig. 29 Tuberculosis therapeutics market: Dosage form movement analysis & market share 2022 & 2030
• Fig. 30 Tablets market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 31 Capsules market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 32 Injections market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 33 Others market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 34 Tuberculosis therapeutics market: Distribution channel outlook and key takeaways
• Fig. 35 Tuberculosis therapeutics market: Distribution channel movement analysis & market share 2022 & 2030
• Fig. 36 Hospital pharmacy market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 37 Retail pharmacy market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 38 Online pharmacy market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 39 Others market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 40 Regional Marketplace: Key Takeaways
• Fig. 41 Regional Outlook, 2022 & 2030
• Fig. 42 Regional Market Dashboard
• Fig. 43 Regional Market Place: Key Takeaways
• Fig. 44 North America, SWOT Analysis
• Fig. 45 Europe, SWOT Analysis
• Fig. 46 Asia Pacific, SWOT Analysis
• Fig. 47 Latin America, SWOT Analysis
• Fig. 48 MEA, SWOT Analysis
• Fig. 49 North America
• Fig. 50 North America Market Estimates And Forecast, 2018 - 2030 (USD Million)
• Fig. 51 U.S.
• Fig. 52 U.S. Market Estimates And Forecast, 2018 - 2030 (USD Million)
• Fig. 53 Canada
• Fig. 54 Canada Market Estimates And Forecast, 2018 - 2030 (USD Million)
• Fig. 55 Europe
• Fig. 56 Europe Market Estimates And Forecast, 2018 - 2030 (USD Million)
• Fig. 57 U.K.
• Fig. 58 U.K. Market Estimates And Forecast, 2018 - 2030 (USD Million)
• Fig. 59 Germany
• Fig. 60 Germany Market Estimates And Forecast, 2018 - 2030 (USD Million)
• Fig. 61 France
• Fig. 62 France Market Estimates And Forecast, 2018 - 2030 (USD Million)
• Fig. 63 Italy
• Fig. 64 Italy Market Estimates And Forecast, 2018 - 2030 (USD Million)
• Fig. 65 Spain
• Fig. 66 Spain Market Estimates And Forecast, 2018 - 2030 (USD Million)
• Fig. 67 Denmark
• Fig. 68 Denmark Market Estimates And Forecast, 2018 - 2030 (USD Million)
• Fig. 69 Sweden
• Fig. 70 Sweden Market Estimates And Forecast, 2018 - 2030 (USD Million)
• Fig. 71 Norway
• Fig. 72 Norway Market Estimates And Forecast, 2018 - 2030 (USD Million)
• Fig. 73 Asia Pacific
• Fig. 74 Asia-Pacific Market Estimates And Forecast, 2018 - 2030 (USD Million)
• Fig. 75 Japan
• Fig. 76 Japan Market Estimates And Forecast, 2018 - 2030 (USD Million)
• Fig. 77 China
• Fig. 78 China Market Estimates And Forecast, 2018 - 2030 (USD Million)
• Fig. 79 India
• Fig. 80 India Market Estimates And Forecast, 2018 - 2030 (USD Million)
• Fig. 81 Australia
• Fig. 82 Australia Market Estimates And Forecast, 2018 - 2030 (USD Million)
• Fig. 83 Thailand
• Fig. 84 Thailand Market Estimates And Forecast, 2018 - 2030 (USD Million)
• Fig. 85 South Korea
• Fig. 86 South Korea Market Estimates And Forecast, 2018 - 2030 (USD Million)
• Fig. 87 Latin America
• Fig. 88 Latin America Market Estimates And Forecast, 2018 - 2030 (USD Million)
• Fig. 89 Brazil
• Fig. 90 Brazil Market Estimates And Forecast, 2018 - 2030 (USD Million)
• Fig. 91 Mexico
• Fig. 92 Mexico Market Estimates And Forecast, 2018 - 2030 (USD Million)
• Fig. 93 Argentina
• Fig. 94 Argentina Market Estimates And Forecast, 2018 - 2030 (USD Million)
• Fig. 95 MEA
• Fig. 96 MEA Market Estimates And Forecast, 2018 - 2030 (USD Million)
• Fig. 97 South Africa
• Fig. 98 South Africa Market Estimates And Forecast, 2018 - 2030 (USD Million)
• Fig. 99 Saudi Arabia
• Fig. 100 Saudi Arabia Market Estimates And Forecast, 2018 - 2030 (USD Million)
• Fig. 101 UAE
• Fig. 102 UAE Market Estimates And Forecast, 2018 - 2030 (USD Million)
• Fig. 103 Kuwait
• Fig. 104 Kuwait Market Estimates And Forecast, 2018 - 2030 (USD Million)
• Fig. 105 Strategy Mapping